Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of 1 of the following:
• * Histologically or cytologically proven prostate adenocarcinoma
• * Multiple sclerotic bone metastases with PSA ≥ 100 ng/mL without histological confirmation
• Radiological evidence of bone metastasis
• Prior hormonal therapy for prostate cancer including ≥ 1 of the following:
• * Bilateral orchidectomy
• * Medical castration by luteinizing hormone-releasing hormone (LHRH) agonist therapy
• * If receiving LHRH agonist therapy alone, this therapy should be continued
• Documented disease progression, defined by one of the following:
• * Progressive disease after discontinuing hormone therapy
• * Elevated and rising PSA, defined as 2 consecutive increases in PSA documented over a previous reference value
• * PSA \> 5ng/mL
• * Progression of any unidimensionally or bidimensionally measurable malignant lesion
• * At least 1 new lesion identified on bone scan
• No known brain or leptomeningeal metastases
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• Life expectancy ≥ 3 months
• Hemoglobin ≥ 10g/dL
• ANC ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Creatinine ≤ 1.5 times upper limit of normal (ULN)
• ALT and AST ≤ 1.5 times ULN (unless related to hepatic metastatic disease, where patients may be entered after discussion with one of the clinical advisors)
• Serum bilirubin ≤ 1.5 times ULN
• Physically fit enough to receive trial treatment
• No malignant disease within the past 5 years, other than adequately treated basal cell carcinoma
• No symptomatic peripheral neuropathy ≥ grade 2 (NCI CTC)
• No known hypersensitivity to bisphosphonates
• No condition, in the opinion of the investigator, that may interfere with the safety of the patient or evaluation of the study objectives
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• At least 4 weeks since prior flutamide, nilutamide, or cyproterone acetate with evidence of disease progression since cessation
• At least 6 weeks since prior bicalutamide with evidence of disease progression since cessation
• At least 4 weeks since prior estramustine and any adverse events must have resolved
• At least 2 months since prior treatment with a bisphosphonate for any reason
• No treatment with any other investigational compound within the past 30 days
• No prior cytotoxic chemotherapy for hormone refractory prostate cancer (HRPC), other than estramustine monotherapy
• No prior radionuclide therapy for HRPC
• No prior radiotherapy to more than 25% of the bone marrow or whole pelvic irradiation
• No concurrent enrollment in any other investigational clinical trial